Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience

Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience

Abstract is missing (Short communication)

Bibliographic Details
Main Authors:	Danielle Rogner, Tilo Biedermann, Felix Lauffer
Format:	Article
Language:	English
Published:	Medical Journals Sweden 2022-03-01
Series:	Acta Dermato-Venereologica
Subjects:	atopic dermatitis JAK-inhibition Baricitinib
Online Access:	https://medicaljournalssweden.se/actadv/article/view/1088

Similar Items

Current views on the pathogenesis and treatment of atopic dermatitis in adults. Experience with the JAK inhibitor baricitinib in patients with moderate to severe atopic dermatitis
by: E. V. Svechnikova, et al.
Published: (2022-04-01)

Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
by: Sihan Wang, et al.
Published: (2025-01-01)

Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry
by: Celeste M. Boesjes, et al.
Published: (2022-11-01)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
by: Novin Nezamololama, et al.
Published: (2020-11-01)

Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results
by: Linde deWijs, et al.
Published: (2022-12-01)

Efficacy of baricitinib 4 mg in patients with moderate‐to‐severe atopic dermatitis previously treated with systemic therapy
by: Antonio Costanzo, et al.
Published: (2023-09-01)

Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors
by: Chisa Nakashima, et al.
Published: (2022-01-01)

Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years
by: Andreas Wollenberg, et al.
Published: (2024-12-01)

JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results
by: Krzysztof Szalus, et al.
Published: (2020-11-01)

Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children
by: Huijuan Fang, et al.
Published: (2024-06-01)

Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4+ cells
by: Shuang Chen, et al.
Published: (2024-02-01)

Baricitinib as monotherapy and with topical corticosteroids in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of dose-response
by: Ibrahim H. I. Almoghayer, et al.
Published: (2024-11-01)

Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis
by: Jacob P. Thyssen, et al.
Published: (2023-12-01)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
by: Teppei Hagino, et al.
Published: (2023-12-01)

Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial
by: Jacob P. Thyssen, et al.
Published: (2023-12-01)

Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
by: Thomas Bieber, et al.
Published: (2023-12-01)

A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis
by: Sang-Doo Lee, MD, et al.
Published: (2022-12-01)

Impact of Baricitinib on Patients’ Quality of Life after One Year of Treatment for Atopic Dermatitis in Real-World Practice: Results of the Observatory of Chronic Inflammatory Skin Diseases Registry
by: Ziad Reguiai, et al.
Published: (2023-10-01)

Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): A Danish Real-world Evidence Atopic Dermatitis Treatment Registry
by: Henrik Hedegaard Pliess Larsen, et al.
Published: (2022-08-01)

Baricitinib Lipid-Based Nanosystems as a Topical Alternative for Atopic Dermatitis Treatment
by: Núria Garrós, et al.
Published: (2023-06-01)

JAK-inhibitors as rescue therapy in dupilumab-refractory severe atopic dermatitis: A case series of 6 patients
by: Neda Shahriari, MD, et al.
Published: (2023-03-01)

Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study – il AD (Italian landscape atopic dermatitis)
by: Luigi Gargiulo, et al.
Published: (2024-12-01)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023-01-01)

Atopic dermatitis: a brief review of recent advances in management
by: Sultan Daghafak Alenazi
Published: (2023-05-01)

Modern treatment methods in atopic dermatitis - literature overview
by: Martyna Borowska-Łygan, et al.
Published: (2025-01-01)

Comparative effectiveness of treatments on time to remission in atopic dermatitis: real-world insights
by: Emi Sato, et al.
Published: (2024-06-01)

Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch
by: José-Manuel Carrascosa, et al.
Published: (2024-05-01)

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies
by: Eric L. Simpson, et al.
Published: (2024-07-01)

Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib
by: Giuseppe Russo, et al.
Published: (2024-04-01)

Research progress on abrocitinib in the treatment of moderate and severe atopic dermatitis
by: Xu ZHU, et al.
Published: (2023-08-01)

Understanding and Managing Atopic Dermatitis: Insights into Pathogenesis and Treatment Strategies
by: Kamila Szewczyk, et al.
Published: (2024-09-01)

Treatment of Atopic Dermatitis Using JAK Inhibitors: A Systematic Review
by: Stefan Siedlikowski, et al.
Published: (2019-11-01)

Current and Emerging Therapies for Atopic Dermatitis in the Elderly
by: Teng Y, et al.
Published: (2023-10-01)

Real‐life case‐series experience with tralokinumab in patients with severe atopic dermatitis
by: Francesca Caroppo, et al.
Published: (2024-03-01)

Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis
by: Minori Sasakura, et al.
Published: (2024-04-01)

Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies
by: Toshiaki Kogame, et al.
Published: (2023-07-01)

Concurrent Refractory Atopic Dermatitis and Generalized Vitiligo Successfully Treated with Abrocitinib: A Case Report
by: Shao X, et al.
Published: (2024-12-01)

Application of Baricitinib in Dermatology
by: Zhang J, et al.
Published: (2022-03-01)

Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
by: Owji S, et al.
Published: (2022-10-01)

Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK Inhibitors
by: Mark G. Kirchhof, et al.
Published: (2024-08-01)